Autolus Therapeutics (AUTL) Announces Proposed Public Offering in the United States

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each ADS representing one ordinary share. All ADSs to be sold in the proposed offering will be offered by Autolus. Autolus also intends to grant the underwriters a 30-day option to purchase up to 15 percent of the ADSs sold in connection with the offering at the public offering price, on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.

Jefferies LLC, William Blair & Company, L.L.C. and Wells Fargo Securities, LLC are acting as joint bookrunners for the offering.

You May Also Be Interested In

• William Blair Starts Terawulf Inc. (WULF) at Outperform
• Jefferies Starts SBI Funds Management (SBIFUNDS:IN) at Buy
• Volitionrx Limited (VNRX) files for 10M share offering by selling stockholders